ClinicalTrials.gg
CompletedNCT01186939Updated Nov 14, 2019Results posted

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

A Phase 3 interventional study of Azacitidine in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 22 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-14.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Apr 2007, registered Aug 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
54th of 126
40 · median 38
Started
2007
with 3 others
Phase 3
9 of 130
1 open now
Registered
40th of 130
by date
Lead sponsor
14 of 130
Celgene

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 54th largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2007, is one of 9 in phase 3, and was the 40th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

At the conclusion of study AZA PH GL 2003 CL 001 (NCT00071799), eligible participants could be enrolled in an optional extension phase in order to continue treatment with azacitidine until it became commercially available; the continued treatment was for ethical and safety reasons only and not to provide additional efficacy data.

Read the detailed description

At the conclusion of study AZA PH GL 2003 CL 001 (NCT00071799), eligible participants could be enrolled in an optional extension phase in order to continue treatment with azacitidine until it became commercially available; the continued treatment was for ethical and safety reasons only and not to provide additional efficacy data.

During the extension phase, participants were treated based on 28-day cycles and monitored for hematologic, nonhematologic, and renal toxicities. Recommended monitoring procedures included complete blood count with differential and platelets at least once each cycle prior to dosing and as needed, bone marrow biopsy and aspirate as clinically indicated, and additional tests or more frequent monitoring at the investigator's discretion based on the patient's clinical status. The azacitidine dose could be modified for toxicities. Laboratory data were not collected during the extension phase.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Myelodysplastic Syndromes
  • MDS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants were considered eligible if they had been randomized to azacitidine treatment in the primary study and were receiving azacitidine at the time of study closure, had completed 12 months of treatment and observation in the primary study, and had signed the document for the extension phase of the study.
  • See study: AZA PH GL 2003 CL 001 for a list of inclusion criteria for the primary study.

Exclusion criteria

Exclusion Criteria:

  • None specific to the extension phase of the study
  • See study: AZA PH GL 2003 CL 001 for a list of exclusion criteria for the primary study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Azacitidine

    Azacitidine (study drug) plus best supportive care.

    Drug: Azacitidine

Interventions

  • Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.

    Also known as: AZA

06

What researchers measure

Primary outcomes

  1. Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period

    Participant counts for a variety of subsets of treatment emergent adverse events (TEAEs)during the extension study period (43-68 months). Subsets include participants counts for serious TEAEs, serious TEAEs that the investigator evaluated as releated to treatment, TEAEs leading to discontinuation of therapy, or a dose reduction, or a dose interruption.

    Time frame: 43- 68 months

07

Results

Posted Sep 21, 2010

Participant flow

Participant flow — Overall Study
MilestoneAzacitidine
Started40
Completed0
Not completed40
Withdrew: Death7
Withdrew: Withdrawal by subject2
Withdrew: No longer receiving clinical benefit17
Withdrew: Program closed5
Withdrew: Sponsor decision4
Withdrew: Started additional treatment1
Withdrew: Nci ctc grade 3 or 4 toxicity1
Withdrew: Myocardial infarction1
Withdrew: Bone marrow transplant1
Withdrew: Transformation to aml1

Outcome measures

PrimaryNumber of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period

Participant counts for a variety of subsets of treatment emergent adverse events (TEAEs)during the extension study period (43-68 months). Subsets include participants counts for serious TEAEs, serious TEAEs that the investigator evaluated as releated to treatment, TEAEs leading to discontinuation of therapy, or a dose reduction, or a dose interruption.

Time frame:
43- 68 months
Reported as:
Number · participants
Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period
participantsAzacitidine
Participants with >=1 treatment emergent AE (TEAE)39
Participants with >=1 treatment related TEAE27
Participants with >=1 serious TEAE20
Participants with >=1 serious trtment related TEAE5
Participants w TEAE leading to discontinued treat15
Participants w TEAE leading to dose reduction4
Participants w TEAE leading to dose interruption15

Adverse events

Collected over Extension study covering 43- 68 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azacitidine—20/40 (50%)36/40 (90%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventAzacitidine
Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/40
AnaemiaBlood and lymphatic system disorders2/40
PneumoniaInfections and infestations2/40
Febrile neutropeniaBlood and lymphatic system disorders1/40
ThrombocytopeniaBlood and lymphatic system disorders1/40
Acute myocardial infarctionCardiac disorders1/40
Angina pectorisCardiac disorders1/40
Cardiac arrestCardiac disorders1/40
Cardiac failureCardiac disorders1/40
Cardiac failure congestiveCardiac disorders1/40
Most frequent other events
Showing 10 of 41
Most frequent other events
EventAzacitidine
ThrombocytopeniaBlood and lymphatic system disorders17/40
NeutropeniaBlood and lymphatic system disorders13/40
AnaemiaBlood and lymphatic system disorders11/40
DiarrhoeaGastrointestinal disorders10/40
Injection site reactionGeneral disorders8/40
PyrexiaGeneral disorders7/40
NauseaGastrointestinal disorders6/40
FatigueGeneral disorders6/40
Oedema peripheralGeneral disorders5/40
NasopharyngitisInfections and infestations5/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)Azacitidine
Mean68.6 ± 8.23
Sex: Female, Male
Sex: Female, Male(Participants)Azacitidine
Female8
Male32
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Azacitidine
Caucasian40
French-American-British (FAB) Classification
French-American-British (FAB) Classification(participants)Azacitidine
Refractory anemia with excess blasts (RAEB)27
RAEB in transformation10
Modified chronic myelomonocytic leukemia1
Acute myeloid leukemia1
Myeloproliferative disease1
World Health Organization (WHO) Classification
World Health Organization (WHO) Classification(participants)Azacitidine
Refractory anemia with excess blasts - 15
Refractory anemia with excess blasts - 222
Chronic myelomonocytic leukemia - 1 (CMMoL-1)0
Chronic myelomonocytic leukemia - 2 (CMMoL-2)2
Acute myeloid leukemia11
International Prognostic Scoring System (IPSS)
International Prognostic Scoring System (IPSS)(participants)Azacitidine
Intermediate risk level 1 (0.5-1.0)1
Intermediate risk level 2 (1.5-2.0)21
High risk (2.5-3.5)14
Not applicable2
Indeterminate2
08

Study locations

22 sites
  • East Melbourne, Victoria, Australia
  • Herston, Australia
  • Perth, Australia
  • Woolloongabba, Australia
  • Plovdiv, Bulgaria
  • Aulnay Sous Bois Cedex, France
  • Berlin, Germany
  • Dusseldorf, Germany
  • Essen, Germany
  • Kiel, Germany
  • Heraklio, Crete, Greece
  • Haidari, Greece
  • Budapest, Hungary
  • Bologna, Italy
  • Firenze, Italy
  • Genova, Italy
  • Rome, Italy
  • Nijmegen, Netherlands
  • Lodz, Poland
  • Avda Campanar, Spain
  • Leon, Spain
  • London, United Kingdom
09

References and documents

Publications

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. PubMed 19230772 ↗
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21. PubMed 20026804 ↗
  • Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellstrom-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 Jul;98(7):1067-72. doi: 10.3324/haematol.2012.074831. Epub 2013 Apr 12. PubMed 23585522 ↗
  • Savona MR, Kolibaba K, Conkling P, Kingsley EC, Becerra C, Morris JC, Rifkin RM, Laille E, Kellerman A, Ukrainskyj SM, Dong Q, Skikne BS. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018 Oct;93(10):1199-1206. doi: 10.1002/ajh.25216. Epub 2018 Sep 3. PubMed 30016552 ↗
  • Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellstrom-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27. doi: 10.1016/j.critrevonc.2010.04.005. Epub 2010 May 6. PubMed 20451404 ↗
  • Garcia-Manero G, Scott BL, Cogle CR, Boyd TE, Kambhampati S, Hetzer J, Dong Q, Kumar K, Ukrainskyj SM, Beach CL, Skikne BS. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leuk Res. 2018 Sep;72:79-85. doi: 10.1016/j.leukres.2018.08.001. Epub 2018 Aug 3. PubMed 30114559 ↗
  • Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open. 2018 Jul 23;8(7):e019955. doi: 10.1136/bmjopen-2017-019955. PubMed 30037860 ↗
  • de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock C. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018 Oct;24(10):2017-2024. doi: 10.1016/j.bbmt.2018.06.016. Epub 2018 Jun 20. PubMed 29933073 ↗
  • Wehmeyer J, Zaiss M, Losem C, Schmitz S, Niemeier B, Harde J, Hannig CV, Harich HD, Muller J, Klausmann M, Tessen HW, Potthoff K. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). Eur J Haematol. 2018 Dec;101(6):766-773. doi: 10.1111/ejh.13160. Epub 2018 Oct 25. PubMed 30091166 ↗
  • Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stolzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hanel M, Duhrsen U, Schetelig J, Rollig C, Kramer M, Ehninger G, Bornhauser M, Thiede C. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12. PubMed 30442503 ↗
  • Boutault R, Peterlin P, Boubaya M, Sockel K, Chevallier P, Garnier A, Guillaume T, Le Bourgeois A, Debord C, Godon C, Le Bris Y, Theisen O, Kroschinsky F, Moreau P, Bene MC, Platzbecker U, Eveillard M. A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. Br J Haematol. 2018 Dec;183(5):736-746. doi: 10.1111/bjh.15626. Epub 2018 Nov 8. PubMed 30406952 ↗
  • Wenk C, Garz AK, Grath S, Huberle C, Witham D, Weickert M, Malinverni R, Niggemeyer J, Kyncl M, Hecker J, Pagel C, Mulholland CB, Muller-Thomas C, Leonhardt H, Bassermann F, Oostendorp RAJ, Metzeler KH, Buschbeck M, Gotze KS. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis. Blood Adv. 2018 Dec 11;2(23):3447-3461. doi: 10.1182/bloodadvances.2018022053. PubMed 30518537 ↗
  • Zeidan AM, Klink AJ, McGuire M, Feinberg B. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Leuk Lymphoma. 2019 Aug;60(8):2050-2055. doi: 10.1080/10428194.2018.1551538. Epub 2019 Jan 14. PubMed 30636526 ↗
  • Leung KK, Nguyen A, Shi T, Tang L, Ni X, Escoubet L, MacBeth KJ, DiMartino J, Wells JA. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):695-700. doi: 10.1073/pnas.1813666116. Epub 2018 Dec 24. PubMed 30584089 ↗
  • Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019 Mar 1;37(7):580-588. doi: 10.1200/JCO.18.00889. Epub 2019 Jan 17. PubMed 30653424 ↗
  • Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011 Jun 15;117(12):2697-702. doi: 10.1002/cncr.25774. Epub 2011 Jan 10. PubMed 21656747 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2007 to primary completion in Sep 2009, 29 months.

Results were first posted in Sep 2010, 1 year after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 29 months is below that.

Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2010
First posted
Aug 23, 2010
StartActual
Apr 1, 2007
Primary completionActual
Sep 1, 2009
CompletionActual
Sep 1, 2009
Results first posted
Sep 21, 2010
Last update
Nov 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01186939
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Aug 23, 2010
Start date
Apr 1, 2007
Primary completion
Sep 1, 2009
Completion
Sep 1, 2009
Results posted
Sep 21, 2010
Last update
Nov 14, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion